BioMarin Pharmaceutical Inc. (BMRN) — Fair Value Analysis

Base-case fair value (P50): $56.44 · Current price: $60.02 · Verdict: Fairly Valued

The Verdict on BMRN

Our Monte Carlo simulations indicate that BIOMARIN PHARMACEUTICAL INC (BMRN) is currently Fairly Valued. With the stock trading at $60.02, our median fair value (P50) stands at $56.44. This suggests a -6.0% divergence from its intrinsic value, positioning BMRN within a reasonable range when considering a multitude of forward-looking scenarios. The "Fairly Valued" verdict is a direct outcome of this analysis, reflecting that the current market price is closely aligned with the central tendency of our probabilistic valuation models.

How BMRN stacks up against peers

BMRN’s operational and financial health is assessed as average within its sector. This quality tier, combined with the -6.0% difference between $60.02 and our $56.44 fair value, paints a balanced picture. While an average quality tier suggests neither significant outperformance nor underperformance relative to sector peers on fundamental metrics, the Monte Carlo analysis indicates that the current market price already discounts this reality effectively. Investors should note this alignment between market price and median fair value, rather than expecting a substantial re-rating purely based on an average quality standing.

What this means for investors

For investors considering BMRN, the -6.0% suggests that the stock is neither significantly undervalued nor overvalued at $60.02 relative to its $56.44 fair value. While a downside scenario is always possible, our Monte Carlo framework does not indicate a material mispricing at present. The fact that BMRN is deemed "Fairly Valued" provides a clear signal derived from thousands of simulated future outcomes, emphasizing the current price's proximity to a robust probabilistic median. To see the full bear/bull distribution and track BMRN's fair value as new fundamentals are released, sign up for FairCurve.